Clinical Trial

Hyperbaric Oxygen Therapy for Metabolic Dysfunction-associated Steatotic Liver Diseases

Study acronym: MASLD
Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated October 1, 2024 (before its estimated August 1, 2026 completion). Its status may not reflect the trial's current state.
Summary
The goal of this clinical trial is to learn if hyperbaric oxygen therapy (HBOT) works to treat Metabolic Dysfunction-associated Steatotic Liver Diseases (MASLD). The main questions it aims to answer are: Does HBOT decreases the fat content and fibrosis state of liver in adult MASLD patients? Does HBOT improves the liver function and metabolic condition in adult MASLD patients? Participants will: Receive HBOT for 20 times in 1 month or recerive regular drug; Visit the clinic for checkups and tests at the starting, ending of the therapy and 6 month after the therapy.
Trial Details
NCT Number NCT06619808
Lead Sponsor Jinling Hospital, China
Conditions Metabolic Dysfunction-associated Steatotic Liver Disease, Hepatic Steatosis, Non-alcoholic Fatty Liver Diseases
Enrollment 150 participants
Start Date 2024-07-29
Primary Completion 2026-08-01 (estimated)
Study Completion 2026-08-31 (estimated)
Updated on ClinicalTrials.gov 2024-10-01